+ND Capital
VC Fund
San Mateo, United States
+ND Capital (NanoDimension) is a venture capital firm founded in 2002 that invests in disruptive technologies across the life, physical, and data sciences.
- Total investments:
- 74
- Last investment:
- Lead investor:
- 31%
- Fund size:
- $335M
- Last fund:
Last updated:
For AI agents: llms.txt
Industries +ND Capital invests in
Stages +ND Capital invests in
Countries +ND Capital invests in
Round sizes
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
| See all 9 contacts → | |||
Round size
- Series A
- $10M–$60M
- Series B
- $13M–$100M
- Series C
- $12M–$67M
Investment Focus
Industry
- Biotechnology 21 (28%)
- Health Care 17 (23%)
- Medical 11 (15%)
- Therapeutics 7 (9%)
- Pharmaceutical 7 (9%)
Stage
- Series B 14 (19%)
- Series A 10 (14%)
- Series C 10 (14%)
- Series D 7 (9%)
- Funding Round 6 (8%)
Country
- United States 23 (31%)
- Switzerland 4 (5%)
- United Kingdom 3 (4%)
- Denmark 2 (3%)
- Canada 1 (1%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
Eric Moessinger
Partner
|
Partner | Total investments: 26 | Find email | |
Jonathan Nicholson
Director
|
Director | Total investments: 0 | Find email | |
Kirill Kuzmichev
Principal
|
Principal | Total investments: 0 | Find email | |
Louis-Philippe Lalonde
Entrepreneur-In-Residence
|
Entrepreneur-In-Residence | Total investments: 0 | Find email | |
Richard Coles
Director
|
Director | Total investments: 0 | Find email | |
| See all 9 team members → | ||||
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Lightcast Discovery
|
Lightcast uses a microfluidic platform to make advances towards unique clinical approaches, new therapies, and innovative products.The company's mission is to push the boundaries of complex cell analysis. Using the Lightcast platform, the company is working with major pharmaceutical companies and leading academic institutes to enable them todiscover more. The Lightcast platform allows precise and highly flexible independent control of thousands of droplets. By combining droplets containing different cells, reporters or other reagents we can perform complex workflows without the need to manipulate cells by hand.Lightcast Discovery was founded in 2019 by Cameron Frayling. | $27M / Venture - Series Unknown / Apr 14, 2026 | |
SPARK Microsystems
|
SPARK Microsystems is a fabless semiconductor company that is leading the way towards ultra-low power wireless communications for the Internet of Things revolution. With its patented technologies, SPARK Microsystems will bring to market a high performance wireless transceiver that allows for orders of magnitude improved power consumption andlatency while providing higher data rates than competing technologies. For more information, please visit www.sparkmicro.com. | $12.4M / Series B / Mar 23, 2026 | |
Syndex Bio
|
Syndex Bio is a biotechnology platform offering molecular technologies and AI for the diagnosis and treatment of disease. | $15.5M / Seed / Feb 23, 2026 | |
Visby Medical
|
Visby Medical is a diagnostics company that develops PCR-based diagnostic tests for the detection of infectious diseases. The company develops a device platform that aims to redefine the way an illness is tested and treated. They believe that by taking a human-centric, technology-first approach to device development and they can create tools thatare both highly accurate and delightful to use. | $55M / Venture - Series Unknown / Jun 17, 2025 | |
HAYA Therapeutics
|
HAYA Therapeutics is a biotechnology company developing precision RNA-guided medicines that target the dark genome. The company leverages its proprietary platform to uncover new insights into disease-associated cell states and the long non-coding RNAs (lncRNAs) that control them. Its lead candidate, HTX-001, is being developed as a potentialtreatment for heart failure. In addition, the company is advancing a pipeline of precision therapies that target lncRNAs for cell-specific treatment of conditions affecting other tissues. | $65M / Series A / May 08, 2025 | |
AIRNA
|
AIRNA is a biotech company that is pioneering RNA editing therapies to improve the health of individuals suffering from both rare and common ailments. | $155M / Series B / Apr 01, 2025 | |
Constructive Bio
|
Constructive is a ground-breaking method for creating wholly artificial genomes and rewriting the genetic code of living things. | $57.7M / Series A / Sep 24, 2024 | |
Vandria
|
Vandria creates mitophagy inducers that renew cells in order to address aging and chronic disorders. | $10.1M / Series A / Aug 21, 2024 | |
|
AIRNA
|
AIRNA is a biotech company that is pioneering RNA editing therapies to improve the health of individuals suffering from both rare and common ailments. | $60M / Series A / Jul 31, 2024 | |
PulseSight Therapeutics
|
PulseSight is an ophthalmology drug development company creating novel, non-viral gene therapies with minimally invasive delivery technology to address the unmet need for treatments against severe retinal diseases leading to blindness. | Seed / Feb 28, 2024 | |
| See all 74 investments → | |||
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Similar stage
Similar country
Featured in Investor Lists
Recommended lists
FAQ
What does +ND Capital invest in?
+ND Capital invests primarily in Biotechnology, Health Care and Medical startups, most often at Series B and Series A stage. Most of the 74 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
What is +ND Capital's check size?
+ND Capital typically joins rounds of $10M–$60M at Series A, $13M–$100M at Series B and $12M–$67M at Series C. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds +ND Capital participates in.
How do I contact +ND Capital?
Public channels for +ND Capital include LinkedIn, X (Twitter) and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at +ND Capital?
The team at +ND Capital includes Eric Moessinger (Partner), Jonathan Nicholson (Director) and Kirill Kuzmichev (Principal), among 9 team members tracked by Shizune. The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Sep 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
